Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor

被引:84
作者
Poux, AN
Cebrat, M
Kim, CM
Cole, PA [1 ]
Marmorstein, R
机构
[1] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
[2] Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA
[4] Univ Wroclaw, Fac Chem, PL-50383 Wroclaw, Poland
关键词
D O I
10.1073/pnas.222373899
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Histone acetyltransferases (HATs) use acetyl CoA to acetylate target lysine residues within histones and other transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequence and substrate preference. Several HAT proteins have been implicated in human cancer. We have previously reported on the preparation of peptide-CoA conjugate inhibitors with distinct specificities for the p300/CBP [cAMP response element binding protein (CREB)-binding protein] or GCN5 HAT subfamilies. Here we report on the crystal structure of the GCN5 HAT bound to a peptide-CoA conjugate containing CoA covalently attached through an isopropionyl linker to Lys-14 of a 20-aa N-terminal fragment of histone H3. Surprisingly, the structure reveals that the H3 portion of the inhibitor is bound outside of the binding site for the histone substrate and that only five of the 20 aa residues of the inhibitor are ordered. Rearrangements within the C-terminal region of the GCN5 protein appear to mediate this peptide displacement. Mutational and enzymatic data support the hypothesis that the observed structure corresponds to a late catalytic intermediate. The structure also provides a structural scaffold for the design of HAT-specific inhibitors that may have therapeutic applications for the treatment of HAT-mediated cancers.
引用
收藏
页码:14065 / 14070
页数:6
相关论文
共 28 条
[1]   Role of the Ada2 and Ada3 transcriptional coactivators in histone acetylation [J].
Balasubramanian, R ;
Pray-Grant, MG ;
Selleck, W ;
Grant, PA ;
Tan, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (10) :7989-7995
[2]   Histone modifications in transcriptional regulation [J].
Berger, SL .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (02) :142-148
[3]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[4]   Crystal structure of the histone acetyltransferase domain of the human PCAF transcriptional regulator bound to coenzyme A [J].
Clements, A ;
Rojas, JR ;
Trievel, RC ;
Wang, L ;
Berger, SL ;
Marmorstein, R .
EMBO JOURNAL, 1999, 18 (13) :3521-3532
[5]   DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes [J].
Costanzo, A ;
Merlo, P ;
Pediconi, N ;
Fulco, M ;
Sartorelli, V ;
Cole, PA ;
Fontemaggi, G ;
Fanciulli, M ;
Schiltz, L ;
Blandino, G ;
Balsano, C ;
Levrero, M .
MOLECULAR CELL, 2002, 9 (01) :175-186
[6]   Structure of the histone acetyltransferase Hat1: A paradigm for the GCN5-related N-acetyltransferase superfamily [J].
Dutnall, RN ;
Tafrov, ST ;
Sternglanz, R ;
Ramakrishnan, V .
CELL, 1998, 94 (04) :427-438
[7]   Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors [J].
Finnin M.S. ;
Donigian J.R. ;
Cohen A. ;
Richon V.M. ;
Rifkind R.A. ;
Marks P.A. ;
Breslow R. ;
Pavletich N.P. .
Nature, 1999, 401 (6749) :188-193
[8]   Expanded lysine acetylation specificity of Gcn5 in native complexes [J].
Grant, PA ;
Eberharter, A ;
John, S ;
Cook, RG ;
Turner, BM ;
Workman, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (09) :5895-5900
[9]   IMPROVED METHODS FOR BUILDING PROTEIN MODELS IN ELECTRON-DENSITY MAPS AND THE LOCATION OF ERRORS IN THESE MODELS [J].
JONES, TA ;
ZOU, JY ;
COWAN, SW ;
KJELDGAARD, M .
ACTA CRYSTALLOGRAPHICA SECTION A, 1991, 47 :110-119
[10]   Mechanism-based inhibition of the melatonin rhythm enzyme: Pharmacologic exploitation of active site functional plasticity [J].
Khalil, EM ;
De Angelis, J ;
Ishii, M ;
Cole, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12418-12423